Skip to main content
Indivior PLC logo

Indivior PLC — Investor Relations & Filings

Ticker · INDV ISIN · GB00BN4HT335 LEI · 213800V3NCQTY7IED471 IL Manufacturing
Open in API
Filings indexed 1,983 across all filing types
Latest filing 2025-01-27 Major Shareholding Noti…
Country GB United Kingdom
Listing IL INDV

About Indivior PLC

https://www.indivior.com/en

Indivior PLC is a global pharmaceutical company that develops, manufactures, and sells medicines to treat substance use disorders (SUD) and serious mental illnesses. The company's primary focus is on pioneering treatments for opioid use disorder (OUD), with a portfolio centered on buprenorphine-based prescription pharmaceuticals. Through its research and development efforts, Indivior aims to address the complex challenges of addiction and behavioral health by providing innovative, life-transforming therapies for patients worldwide.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is clearly identified by the header 'RNS Number : 7819U' and contains the standard format for a regulatory notification disseminated via RNS (the news service of the London Stock Exchange). Specifically, the form title is 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, which corresponds to the definition of Major Shareholding Notification (MRQ). Although RNS is mentioned, MRQ is the more specific classification for a TR-1 filing regarding share ownership thresholds being crossed.
2025-01-27 English
TRANSACTION IN OWN SHARES
Regulatory Filings
2025-01-21 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states it is a 'WEEKLY REPORT' concerning the 'SHARE REPURCHASE PROGRAM' of Indivior PLC. It details the number of ordinary shares purchased for cancellation during a specific period (January 13, 2025, to January 17, 2025) and provides a breakdown of these transactions. This activity directly corresponds to the definition of a company buying back its own shares, which maps to the 'Transaction in Own Shares' category (POS). The presence of the RNS Number and the closing statement confirming the information is provided by RNS further supports this being a regulatory disclosure, but the content is specifically about share repurchases.
2025-01-21 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-01-17 English
Replacement Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states it is a 'SHARE REPURCHASE PROGRAM WEEKLY REPORT - CORRECTION' and details the purchase and cancellation of ordinary shares under a Share Repurchase Program. This directly corresponds to the definition of 'Transaction in Own Shares'. The filing originates from RNS (London Stock Exchange news service), but the content is specific to share repurchases, making 'POS' the most accurate classification over the general 'RNS' fallback. The document length (4540 chars) is substantial enough to be the report itself, not just an announcement of a report.
2025-01-16 English
TRANSACTION IN OWN SHARES
Regulatory Filings
2025-01-14 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.